Ping An Biomedical (PASW) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Jan 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PASW SEC filings page.
Ping An Biomedical (PASW) reported $4.8M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
The dominant mechanic is thin gross economics: modest revenue supports little gross profit while operating costs and financing shape the balance sheet.
Revenue of$4.8M produced only$133K of gross profit, leaving little contribution after direct costs. That thin base sits beside operating cash flow of-$903K , linking the cash drain to an operating model that consumes cash before financing.
The balance sheet is not debt-dominated: liabilities of
Financing supplied
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ping An Biomedical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ping An Biomedical has an operating margin of -43.0%, meaning the company loses $43 on every $100 of revenue. This results in a profitability score of 7/100.
Not available for Ping An Biomedical, and counted as zero in the overall score.
Ping An Biomedical has a moderate D/E ratio of 0.51. This balance of debt and equity financing earns a leverage score of 60/100.
With a current ratio of 2.76, Ping An Biomedical holds $2.76 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.
Not available for Ping An Biomedical, and counted as zero in the overall score.
Ping An Biomedical posts a -28.4% return on equity (ROE), meaning it loses $28 for every $100 of shareholders' equity. This results in a returns score of 8/100.
Ping An Biomedical scores 3.37, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($17.9M) relative to total liabilities ($3.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ping An Biomedical reported a net loss of $1.8M while operations used $903K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Ping An Biomedical reported an operating loss of $2.1M against $43K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Ping An Biomedical held $165K in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
PASW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
PASW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q2'2510-Q |
|---|---|---|
| Total Assets | $9.6M | $6.7M |
| Current Assets | $8.9M | $6.3M |
| Cash & Equivalents | $165K | $15K |
| Short-Term Investments | $0 | $0 |
| Inventory | $62K | $18K |
| Accounts Receivable | $2.4M | $4.1M |
| Long-Term Investments | $0 | $0 |
| Total Liabilities | $3.3M | $8.3M |
| Current Liabilities | $3.2M | $8.3M |
| Non-Current Liabilities | $13K | $40K |
| Total Equity | $6.4M | -$1.6M |
| Retained Earnings | -$3.0M | -$1.7M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
PASW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
PASW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Where Ping An Biomedical Ranks
Frequently Asked Questions
What is Ping An Biomedical's annual revenue?
Ping An Biomedical (PASW) reported $4.8M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Ping An Biomedical profitable?
No, Ping An Biomedical (PASW) reported a net income of -$1.8M in fiscal year 2025, with a net profit margin of -37.6%.
What is Ping An Biomedical's EBITDA?
Ping An Biomedical (PASW) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ping An Biomedical's gross margin?
Ping An Biomedical (PASW) had a gross margin of 2.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ping An Biomedical's operating margin?
Ping An Biomedical (PASW) had an operating margin of -43.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ping An Biomedical's net profit margin?
Ping An Biomedical (PASW) had a net profit margin of -37.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ping An Biomedical's return on equity (ROE)?
Ping An Biomedical (PASW) has a return on equity of -28.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ping An Biomedical's operating cash flow?
Ping An Biomedical (PASW) recorded an outflow of $903K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Ping An Biomedical's total assets?
Ping An Biomedical (PASW) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Ping An Biomedical's current ratio?
Ping An Biomedical (PASW) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.
What is Ping An Biomedical's debt-to-equity ratio?
Ping An Biomedical (PASW) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ping An Biomedical's return on assets (ROA)?
Ping An Biomedical (PASW) had a return on assets of -18.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ping An Biomedical's P/E ratio?
Ping An Biomedical (PASW) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $17.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ping An Biomedical's price-to-sales ratio?
Ping An Biomedical (PASW) trades at 3.7x sales, its market capitalization divided by revenue of $4.8M revenue, FY2025. The market capitalization is $17.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Ping An Biomedical's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Ping An Biomedical (PASW) held $165K in cash, cash equivalents and investments, and reported an operating cash outflow of $903K over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Ping An Biomedical's Altman Z-Score?
Ping An Biomedical (PASW) has an Altman Z-Score of 3.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Are Ping An Biomedical's earnings high quality?
Ping An Biomedical (PASW) reported a net loss of $1.8M while operations used $903K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ping An Biomedical cover its interest payments?
Ping An Biomedical (PASW) reported an operating loss of $2.1M against $43K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ping An Biomedical?
Ping An Biomedical (PASW) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.